TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis C$12.42 -0.03 (-0.24%) As of 05/23/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Cipher Pharmaceuticals Stock (TSE:CPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$12.35▼C$12.4950-Day RangeC$11.04▼C$14.5652-Week RangeC$8.01▼C$19.69Volume8,728 shsAverage Volume33,606 shsMarket CapitalizationC$222.98 millionP/E Ratio13.72Dividend YieldN/APrice TargetC$14.75Consensus RatingModerate Buy Company OverviewCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.Read More… Cipher Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCPH MarketRank™: Cipher Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingCipher Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 13.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 13.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.72.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CPH. News and Social Media2.6 / 5News SentimentN/A News SentimentCipher Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cipher Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for CPH on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Cipher Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$47,215.00 in company stock.Percentage Held by Insiders42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.38% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPH Stock News HeadlinesEarnings call transcript: Cipher Pharmaceuticals misses Q1 2025 EPS expectationsMay 11, 2025 | uk.investing.comEarnings call transcript: Cipher Pharmaceuticals Q4 2024 sees stock surgeMarch 21, 2025 | uk.investing.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.May 24, 2025 | Golden Portfolio (Ad)Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 ResultsMarch 19, 2025 | theglobeandmail.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?March 17, 2025 | uk.finance.yahoo.comCipher Pharmaceuticals Inc. (TSE:CPH) most popular amongst individual investors who own 57%, insiders hold 42%February 4, 2025 | finance.yahoo.comThis Healthcare Stock Could Be the Best Investment of the DecadeJanuary 31, 2025 | msn.com1 Canadian Stock Ready to Start 2025 With a BangJanuary 30, 2025 | fool.caSee More Headlines CPH Stock Analysis - Frequently Asked Questions How have CPH shares performed this year? Cipher Pharmaceuticals' stock was trading at C$14.32 at the beginning of 2025. Since then, CPH shares have decreased by 13.3% and is now trading at C$12.42. View the best growth stocks for 2025 here. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) posted its quarterly earnings data on Thursday, August, 10th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.01. The business earned $7.10 million during the quarter, compared to the consensus estimate of $7.46 million. Cipher Pharmaceuticals had a net margin of 59.92% and a trailing twelve-month return on equity of 17.93%. Read the conference call transcript. How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD). Company Calendar Last Earnings8/10/2023Today5/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$14.75 High Stock Price TargetC$17.00 Low Stock Price TargetC$12.50 Potential Upside/Downside+18.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.91 Trailing P/E Ratio13.72 Forward P/E Ratio9.62 P/E GrowthN/ANet IncomeC$11.41 million Net Margins59.92% Pretax MarginN/A Return on Equity17.93% Return on Assets7.90% Debt Debt-to-Equity Ratio41.22 Current Ratio2.00 Quick Ratio2.67 Sales & Book Value Annual SalesC$19.03 million Price / Sales11.71 Cash FlowC$3.52 per share Price / Cash Flow3.53 Book ValueC$3.96 per share Price / Book3.14Miscellaneous Outstanding Shares17,953,309Free FloatN/AMarket CapC$222.98 million OptionableNot Optionable Beta1.20 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (TSE:CPH) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.